Brief: Hillstream Biopharma Announces Strategic Reprioritization Of Pipeline To Targeting Her2/Her3 Solid Tumors

Canton Strategic Holdings

10/07/2023 14:23

July 10 (Reuters) - Hillstream BioPharma Inc  HILS.O :
    * HILLSTREAM BIOPHARMA ANNOUNCES STRATEGIC REPRIORITIZATION
OF
PIPELINE TO TARGETING HER2/HER3 SOLID TUMORS VIA BISPECIFIC AND
ADC ANTIBODIES AND BIOLOGICS
    * HILLSTREAM BIOPHARMA- LEAD BISPECIFIC ANTIBODY, HSB-3215
DESIGNED TO TARGET NOVEL CONFORMATIONAL EPITOPES ON HIGH VALUE
VALIDATED TARGETS, HER2, HER3
    * HILLSTREAM BIOPHARMA INC- ANNOUNCED APPOINTMENT OF SIREESH
APPAJOSYULA, PHARM.D.AS AS CHIEF OPERATING OFFICER
    * HILLSTREAM BIOPHARMA INC - WILL FOCUS ITS PIPELINE ON
ADVANCING
NOVEL ONCOLOGY ASSETS
    * HILLSTREAM BIOPHARMA INC -  INTENDS TO DEVELOP HSB-3215
NOVEL
BSAB AND FILE AN IND APPLICATION WITH US FDA LATE NEXT YEAR
    * HILLSTREAM BIOPHARMA INC- INTENDS TO FURTHER ENHANCE
COLLABORATIONS WITH APPLIED BIOMEDICAL SCIENCE INSTITUTE (ABSI)
AND MINOTAUR

Source text for Eikon:  ID:nGNX2jdqGp 
Further company coverage:  HILS.O 

 ((Reutersbriefs@thomsonreuters.com;))